Stockscreener 앱 받기
7.80
4.56%
0.34
시간 외 거래:
7.41
-0.39
-5.00%
전일 마감가:
$7.46
열려 있는:
$7.51
하루 거래량:
134.48K
Relative Volume:
0.54
시가총액:
$812.91M
수익:
$106.66M
순이익/손실:
$15.16M
주가수익비율:
83.42
EPS:
0.0935
순현금흐름:
$6.37M
1주 성능:
+5.26%
1개월 성능:
+1.56%
6개월 성능:
-35.00%
1년 성능:
-35.43%
1일 변동 폭
$7.35
$7.86
1주일 범위
$6.98
$7.86
52주 변동 폭
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(619) 949-3681
주소
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
GYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.80 | 812.91M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
Gyre Therapeutics (GYRE) Begins Phase 1 Trial for Pulmonary Hypertension Drug | GYRE Stock News - GuruFocus
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - TradingView
Novel PAH Drug Enters Clinical Trials in $370M China Market, Targeting Rare Disease with High Mortality - Stock Titan
Gyre Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Gyre Therapeutics Closes $23 Million Public Offering - MarketScreener
Gyre Therapeutics Raises $23M in Public Offering for MASH Clinical Trials | GYRE Stock News - Stock Titan
Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Globe and Mail
What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga
GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World
Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus
Gyre Therapeutics Announces Stock Offering Agreement - TipRanks
Gyre Therapeutics announces new stock offering - Investing.com
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Gyre Therapeutics commences underwritten public offering - MSN
Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com
GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus
Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan
Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance
Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus
Gyre Therapeutics tumbles after stock offering launch - TradingView
Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com
Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus
Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025 - Nasdaq
Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan
Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World
Gyre Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq
1 Stock to Buy Hand Over Fist as ‘Risk On’ Sentiment Gains Momentum - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq
Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com
Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance
Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Gyre Therapeutics Inc 주식 (GYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
1.45%
0.86%
자본화:
|
볼륨(24시간):